Celularity

Celularity Deferred Tax Liabilities

The Deferred Tax Liabilities of Celularity (CELU) as of Oct 31, 2026 is 10,000.00 USD. In the previous year, Deferred Tax Liabilities was 10,000.00 USD — a change of 0.00% (lower).

Deferred Tax Liabilities

10,000.00USD

YoY

0.00%

Last updated:

Deferred Tax Liabilities of Celularity is 2024 10,000.00 USD. Deferred Tax Liabilities of Celularity was 2023 10,000.00 USD. It decreases by 0.00% lower compared to the previous year.

The Celularity Deferred Tax Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Deferred Tax Liabilities
Date
Deferred Tax Liabilities
Jan 1, 2020
1,000.00 USD
Jan 1, 2021
10,000.00 USD
Jan 1, 2022
9,000.00 USD
Jan 1, 2023
10,000.00 USD
Jan 1, 2024
10,000.00 USD
The Celularity Deferred Tax Liabilities history
YEARDeferred Tax LiabilitiesYoY
10,000.00USD0.00%
10,000.00USD+11.11%
9,000.00USD-10.00%
10,000.00USD+900.00%
1,000.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Celularity Stock analysis

What does Celularity do? Celularity, Inc. develops off-the-shelf placental-derived allogeneic cell therapies for cancer and immune and infectious diseases. The company operates through three business segments: Cell Therapy, Degenerative Disease, and BioBanking. Its therapy product candidates include CAR-T cells, natural killer cells, mesenchymal-like adherent stromal cells, and exosomes targeting cancer, infectious, and degenerative diseases. The company's cell therapeutic programs include CYCART-19, CYCART-201, CYNK-001, CYNK-301, CYNK-302, APPL-001, and pEXO-001. CYCART-19 is a placental-derived CAR-T cell therapy targeting B-cell malignancies. pEXO-001 is a placental-derived exosome therapy in development. The company generates revenue through the development and commercialization of its cell therapy programs. The Cell Therapy segment focuses on developing therapies for cancer, while the Degenerative Disease segment targets conditions like osteoarthritis and neurodegenerative disorders. BioBanking involves the collection and storage of placental tissue for future therapeutic use. The primary buyers of these therapies are healthcare providers and hospitals treating patients with cancer, immune disorders, and infectious diseases. Celularity's product portfolio includes CYCART-19 for B-cell malignancies, CYNK-001 for solid tumors, and pEXO-001 for regenerative medicine. The company's target market segments are patients with cancer, immune disorders, and infectious diseases. The Degenerative Disease segment specifically addresses conditions such as osteoarthritis and neurodegenerative disorders through its cell therapy programs. BioBanking supports the company's research and development by providing a source of placental-derived cells for therapeutic development. Celularity is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Celularity stock

Deferred Tax Liabilities of Celularity is 10,000.00 USD in 2024.

Deferred Tax Liabilities of Celularity changed from 10,000.00 USD to 10,000.00 USD, representing a 0.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Deferred Tax Liabilities Celularity since 2006 – with annual values, charts, and detailed analysis.

Deferred tax liabilities arise from temporary differences between accounting and tax treatments. They represent taxes owed in the future on income already recognized.

Deferred Tax Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Deferred Tax Liabilities's Celularity historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Celularity

All Key Metrics — Celularity